// App-Quantinova.ai

: Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).

Researchers

Presenter

  • Yu-Wei Chen

Principal Investigators

  • Katy Beckermann

  • Scott Mattox Haake

  • Anupama Reddy

  • Yu Shyr

  • Michael B. Atkins

  • Nataliya Mar

  • Moshe Chaim Ornstein

  • Sumanta Monty Pal

  • Tian Zhang

  • Wendy Kimryn Rathmell

  • Brian I. Rini

Medical Centers

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Cleveland Clinic, Cleveland, OH

  • UC Irvine Health, Orange, CA

  • Vindhya Data Science, Durham, NC

  • City of Hope, Duarte, CA

  • Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • III

Study Id's

  • NCT05361720

Sponsors

  • The department of defense kidney cancer research program clinical trial award

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved